Resource: Polypharmacy references

Resource: Polypharmacy references

+SHARE

Lown Polypharmacy Endnotes References Library

(updated 5/8/2018)

General

  1. Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc 2008; 56(10): 1946-52.
  2. Ballentine NH. Polypharmacy in the elderly: maximizing benefit, minimizing harm. Critical care nursing quarterly 2008; 31(1): 40-5.
  3. Barras MA, Hughes D, Ullner M. Direct oral anticoagulants: New drugs with practical problems. How can nurses help prevent patient harm? Nursing & health sciences 2016; 18(3): 408-11.
  4. Beard K. Drugs in the elderly–more good than harm? Expert opinion on drug safety 2007; 6(3): 229-31.
  5. Brett J, Elshaug AG, Bhatia RS, Chalmers K, Badgery-Parker T, Pearson SA. A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study. Implement Sci 2017; 12(1): 58.
  6. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging 2008; 3(2): 383-9.
  7. Chutka DS, Takahashi PY, Hoel RW. Inappropriate medication use in the elderly. Essential psychopharmacology 2005; 6(6): 331-40.
  8. Fitzgerald RJ. Medication errors: the importance of an accurate drug history. Br J Clin Pharmacol 2009; 67(6): 671-5.
  9. Gillette C, Prunty L, Wolcott J, Broedel-Zaugg. A new lexicon for polypharmacy: Implications for research, practice, and education. Research in Social and Administrative Pharmacy 2015.
  10. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5(4): 345-51.
  11. Jetha S. Polypharmacy, the Elderly, and Deprescribing. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2015; 30(9): 527-32.
  12. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC geriatrics 2017; 17(1): 230.
  13. Mortazavi SS, Shati M, Keshtkar A, Malakouti SK, Bazargan M, Assari S. Defining polypharmacy in the elderly: a systematic review protocol. BMJ open 2016; 6(3): e010989.
  14. Page AT, Potter K, Clifford R, Etherton-Beer C. Deprescribing in older people. Maturitas 2016; 91: 115-34.
  15. Patel CH, Zimmerman KM, Fonda JR, Linsky A. Medication Complexity, Medication Number, and Their Relationships to Medication Discrepancies. The Annals of pharmacotherapy 2016; 50(7): 534-40.
  16. Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. Internal medicine journal 2015; 45(3): 352-6.
  17. Sirois C, Laroche M-L, Guénette L, Kröger E, Cooper D, Émond V. Polypharmacy in multimorbid older adults: protocol for a systematic review. Systematic Reviews 2017; 6(1): 104.
  18. Skinner M. A literature review: polypharmacy protocol for primary care. Geriatric nursing (New York, NY) 2015; 36(5): 367-71.e4.
  19. Stewart D, Gibson-Smith K, MacLure K, et al. A modified Delphi study to determine the level of consensus across the European Union on the structures, processes and desired outcomes of the management of polypharmacy in older people. PLoS One 2017; 12(11): e0188348.
  20. Stewart D, Mair A, Wilson M, et al. Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert opinion on drug safety 2017; 16(2): 203-13.
  21. Stewart RB. Polypharmacy in the elderly: a fait accompli? DICP : the annals of pharmacotherapy 1990; 24(3): 321-3.
  22. Todd A, Nazar H, Pearson H, Andrew L, Baker L, Husband A. Inappropriate prescribing in patients accessing specialist palliative day care services. International journal of clinical pharmacy 2014; 36(3): 535-43.
  23. Walinsky MD. Pharmacologic considerations in the geriatric patient. Clinics in podiatric medicine and surgery 1993; 10(2): 221-30.
  24. Wallis KA. Ageing is not for the faint-hearted: are we making it worse? Polypharmacy-related harm in the elderly. Journal of primary health care 2015; 7(2): 167-9.
  25. Willlams CM. Using medications appropriately in older adults. American family physician 2002; 66(10): 1917-24.
  26. Young SL, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. Journal of psychopharmacology (Oxford, England) 2015; 29(4): 353-62.
  27. Zelko E, Klemenc-Ketis Z, Tusek-Bunc K. Medication Adherence in Elderly with Polypharmacy Living at Home: A Systematic Review of Existing Studies. Mater Sociomed 2016; 28(2): 129-32.

 

Incidence

  1. Drug Use Among Seniors on Public Drug Programs in Canada, 2012: Canadian Institute for Health Information, 2014.
  2. Bala S, Narayan S, Nishtala P. Potentially inappropriate medications in community-dwelling older adults undertaken as a comprehensive geriatric risk assessment. European Journal of Clinical Pharmacology 2018.
  3. Beer C, Hyde Z, Almeida OP, et al. Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study. Br J Clin Pharmacol 2011; 71(4): 592-9.
  4. Blix HS, Viktil KK, Reikvam A, et al. The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol 2004; 60(9): 651-8.
  5. Buck MD, Atreja A, Brunker CP, et al. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. Am J Geriatr Pharmacother 2009; 7(2): 84-92.
  6. Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci 2015; 70(8): 989-95.
  7. Cullinan S, O’Mahony D, Byrne S. Application of the structured history taking of medication use tool to optimise prescribing for older patients and reduce adverse events. International journal of clinical pharmacy 2016; 38(2): 374-9.
  8. Dwyer L, Han B, Woodwell D, Rechntsteiner E. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. American journal of geriatric pharmacotherapy 2010.
  9. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief 2010; (42): 1-8.
  10. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Medicine 2015.
  11. Harrison S, O’Donnell K, Bradley C, et al. Associations between the Drug Burden Index, Potentially Inappropriate Medications and Quality of Life in Residential Aged Care. Drugs and Aging 2018.
  12. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. JAMA 2015; 314(17): 1818-31.
  13. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert opinion on drug safety 2014; 13(1): 57-65.
  14. Mitchell AA, Kaufman DW, Rosenberg L. Patterns of Medication Use in the United States. Boston, MA: The Sloane Epidemiology Center at Boston University, 2007.
  15. Mohammer, Haumann, Morike, Joos. Polypharmacy-an Upward Trend with Unpredictable Effects. Dtsch Arztebl Int 2016.
  16. Moriarty, Hardy, Bennett, Smith, Fahey. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. The BMJ 2015.
  17. Nightingale, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. Journal of Clinical Oncology 2015.
  18. Onder G, Bonassi S, Abbatecola AM, Folino-Gallo P. High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency. The Journals of Gerontology 2013.
  19. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. JAMA Intern Med 2016; 176(4): 473-82.
  20. Redston MR, Hilmer SN, McLachlan AJ, Clough AJ, Gnjidic D. Prevalence of Potentially Inappropriate Medication Use in Older Inpatients with and without Cognitive Impairment: A Systematic Review. J Alzheimers Dis 2018; 61(4): 1639-52.
  21. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood) 2005; Suppl Web Exclusives: W5-152-W5-66.
  22. Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol 2016; 7(5): 346-53.

 

Prevalence

  1. Ble A, Masoli JA, Barry HE, et al. Any versus long-term prescribing of high risk medications in older people using 2012 Beers Criteria: results from three cross-sectional samples of primary care records for 2003/4, 2007/8 and 2011/12. BMC geriatrics 2015; 15: 146.
  2. Breuker C, Abraham O, di Trapanie L, et al. Patients with diabetes are at high risk of serious medication errors at hospital: Interest of clinical pharmacist intervention to improve healthcare. European journal of internal medicine 2017; 38: 38-45.
  3. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children’s hospitals. Pediatrics 2015; 135(1): e99-108.
  4. Feinstein JA, Feudtner C, Valuck RJ, Kempe A. The depth, duration, and degree of outpatient pediatric polypharmacy in Colorado fee-for-service Medicaid patients. Pharmacoepidemiology and drug safety 2015; 24(10): 1049-57.
  5. Garcia-Gollarte F, Baleriola-Julvez J, Ferrero-Lopez I, Cruz-Jentoft AJ. Inappropriate drug prescription at nursing home admission. Journal of the American Medical Directors Association 2012; 13(1): 83.e9-15.
  6. Goulding MR. Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med 2004; 164(3): 305-12.
  7. Guaraldo L, Cano FG, Damasceno GS, Rozenfeld S. Inappropriate medication use among the elderly: a systematic review of administrative databases. BMC geriatrics 2011; 11: 79.
  8. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5(4): 345-51.
  9. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Annals of emergency medicine 2001; 38(6): 666-71.
  10. Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. Journal of the American Medical Directors Association 2015; 16(6): 535 e1-12.
  11. Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008; 65(1): 130-3.
  12. Onder G, Liperoti R, Fialova D, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci 2012; 67(6): 698-704.
  13. Somers M, Rose E, Simmonds D, Whitelaw C, Calver J, Beer C. Quality use of medicines in residential aged care. Australian family physician 2010; 39(6): 413-6.
  14. van den Bemt PM, Chaaouit N, van Lieshout EM, Verhofstad MH. Noncompliance with guidelines on proton pump inhibitor prescription as gastroprotection in hospitalized surgical patients who are prescribed NSAIDs. European journal of gastroenterology & hepatology 2016; 28(8): 857-62.
  15. Woelfel JA, Patel RA, Walberg MP, Amaral MM. Use of potentially inappropriate medications in an ambulatory Medicare population. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2011; 26(12): 913-9.
  16. Yong TY, Lau SY, Li JY, Hakendorf P, Thompson CH. Medication prescription among elderly patients admitted through an acute assessment unit. Geriatrics & gerontology international 2012; 12(1): 93-101.

Rates of Harm

  1. Frailty, polypharmacy and deprescribing. Drug and therapeutics bulletin 2016; 54(6): 69-72.
  2. Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T. Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. Arch Intern Med 2004; 164(5): 545-50.
  3. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365(21): 2002-12.
  4. Carter GL, Dawson AH, Lopert R. Drug-induced delirium. Incidence, management and prevention. Drug safety 1996; 15(4): 291-301.
  5. Chiatti C, Bustacchini S, Furneri G, et al. The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review. Drug safety 2012; 35 Suppl 1: 73-87.
  6. Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children’s Hospitals. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2016; 17(5): e218-28.
  7. Dalleur O, Spinewine A, Henrard S, Losseau C, Speybroeck N, Boland B. Inappropriate prescribing and related hospital admissions in frail older persons according to the STOPP and START criteria. Drugs Aging 2012; 29(10): 829-37.
  8. D’Arcy PF. Iatrogenic disease: a hazard of multiple drug therapy. R Soc Health J 1976; 96(6): 277-83.
  9. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children’s hospitals. Pediatrics 2015; 135(1): e99-108.
  10. Field TS, Mazor KM, Briesacher B, Debellis KR, Gurwitz JH. Adverse drug events resulting from patient errors in older adults. J Am Geriatr Soc 2007; 55(2): 271-6.
  11. Franco JVA, Terrasa SA, Kopitowski KS. Medication discrepancies and potentially inadequate prescriptions in elderly adults with polypharmacy in ambulatory care. J Family Med Prim Care 2017; 6(1): 78-82.
  12. Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 2014; 62(12): 2261-72.
  13. Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN. Drug burden index and beers criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol 2012; 52(2): 258-65.
  14. Hanlon P, Nicholl BI, Jani BD, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ open 2018; 8(1): e018404.
  15. Harkanen M, Kervinen M, Ahonen J, Voutilainen A, Turunen H, Vehvilainen-Julkunen K. Patient-specific risk factors of adverse drug events in adult inpatients – evidence detected using the Global Trigger Tool method. Journal of clinical nursing 2015; 24(3-4): 582-91.
  16. Harrison JK, Van Der Wardt V, Conroy SP, et al. New horizons: the management of hypertension in people with dementia. Age Ageing 2016; 45(6): 740-6.
  17. Karamichalakis N, Georgopoulos S, Vlachos K, et al. Efficacy and safety of novel anticoagulants in the elderly. Journal of geriatric cardiology : JGC 2016; 13(8): 718-23.
  18. Kim J, Parish AL. Polypharmacy and Medication Management in Older Adults. The Nursing clinics of North America 2017; 52(3): 457-68.
  19. Kydd A, Fleming A. What doctors need to know: Prescribing or not for the oldest old. Maturitas 2016; 90: 9-16.
  20. Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf 2016; 7(1): 11-22.
  21. Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross sectional study. BMJ (Clinical research ed) 2003; 327(7417): 712-7.
  22. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. Journal of the American Pharmacists Association; 57(6): 729-38.e10.
  23. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert opinion on drug safety 2014; 13(1): 57-65.
  24. Page RL, 2nd, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother 2006; 4(4): 297-305.
  25. Pilgrim JL, Gerostamoulos D, Drummer OH. Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. International journal of legal medicine 2011; 125(6): 803-15.
  26. Rashid A. Yonder: Self-harm, repeat prescribing, deprescribing, and worry. The British journal of general practice : the journal of the Royal College of General Practitioners 2016; 66(646): 261.
  27. Reis AM, Cassiani SH. Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol 2011; 67(6): 625-32.
  28. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clinics in geriatric medicine 2012; 28(2): 173-86.
  29. Sousa-Veloso T. Practice-Based Research Networks: Integrating Clinical Data for Improved Pharmacoepidemiology. Pain Ther 2016; 5(2): 143-8.
  30. Tsao CH, Tsai CF, Lee YT, et al. Drug Prescribing in the Elderly Receiving Home Care. The American journal of the medical sciences 2016; 352(2): 134-40.
  31. van den Bemt PM, Chaaouit N, van Lieshout EM, Verhofstad MH. Noncompliance with guidelines on proton pump inhibitor prescription as gastroprotection in hospitalized surgical patients who are prescribed NSAIDs. European journal of gastroenterology & hepatology 2016; 28(8): 857-62.
  32. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 2007; 63(2): 187-95.
  33. Weng MC, Tsai CF, Sheu KL, et al. The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases. QJM : monthly journal of the Association of Physicians 2013; 106(11): 1009-15.
  34. Wiese MD, Roberts MS, Hendrix I, Shakib S, Reeve E. The benefits and harms of deprescribing.(Report). The Medical journal of Australia 2014; 201(7): 386-9.
  35. Zhou L, Rupa AP. Categorization and association analysis of risk factors for adverse drug events. Eur J Clin. Pharmacol 2017.
  36. Ziere G, Dieleman JP, Hofman A, Pols HA, van der Cammen TJ, Stricker BH. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 2006; 61(2): 218-23.

 

Barriers and Drivers

  1. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS One 2016; 11(4): e0151066.
  2. Anderson K, Foster M, Freeman C, Luetsch K, Scott I. Negotiating “Unmeasurable Harm and Benefit”: Perspectives of General Practitioners and Consultant Pharmacists on Deprescribing in the Primary Care Setting. Qualitative health research 2017; 27(13): 1936-47.
  3. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ open 2014; 4(12): e006544.
  4. Antimisiaris D, Cutler T. Managing Polypharmacy in the 15-Minute Office Visit. Primary care 2017; 44(3): 413-28.
  5. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294(6): 716-24.
  6. Farrell B, Pottie K, Rojas-Fernandez CH, Bjerre LM, Thompson W, Welch V. Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. PLoS One 2016; 11(8): e0161248.
  7. Farrell B, Richardson L, Raman-Wilms L, de Launay D, Alsabbagh MW, Conklin J. Self-efficacy for deprescribing: A survey for health care professionals using evidence-based deprescribing guidelines. Research in social & administrative pharmacy : RSAP 2018; 14(1): 18-25.
  8. Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. PLoS One 2015; 10(4): e0122246.
  9. Fried TR, Tinetti ME, Iannone L. Primary care clinicians’ experiences with treatment decision making for older persons with multiple conditions. Arch Intern Med 2011; 171(1): 75-80.
  10. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf 2015; 6(6): 212-33.
  11. Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clinics in geriatric medicine 2012; 28(2): 159-72.
  12. Ie K, Felton M, Springer S, Wilson SA, Albert SM. Physician Factors Associated with Polypharmacy and Potentially Inappropriate Medication Use. J Am Board Fam Med 2017; 30(4): 528-36.
  13. Linsky A, Meterko M, Stolzmann K, Simon SR. Supporting medication discontinuation: provider preferences for interventions to facilitate deprescribing. BMC health services research 2017; 17(1): 447.
  14. Linsky A, Simon SR. Patients’ perceptions of their “most” and “least” important medications: a retrospective cohort study. BMC research notes 2012; 5: 619.
  15. Linsky A, Simon SR, Bokhour B. Patient perceptions of proactive medication discontinuation. Patient education and counseling 2015; 98(2): 220-5.
  16. Linsky A, Simon SR, Marcello TB, Bokhour B. Clinical provider perceptions of proactive medication discontinuation. The American journal of managed care 2015; 21(4): 277-83.
  17. Linsky A, Simon SR, Stolzmann K, Meterko M. Patient attitudes and experiences that predict medication discontinuation in the Veterans Health Administration. Journal of the American Pharmacists Association : JAPhA 2018; 58(1): 13-20.
  18. Mishra SI, Gioia D, Childress S, Barnet B, Webster RL. Adherence to medication regimens among low-income patients with multiple comorbid chronic conditions. Health & social work 2011; 36(4): 249-58.
  19. Ni Chroinin D, Ni Chroinin C, Beveridge A. Factors influencing deprescribing habits among geriatricians. Age Ageing 2015; 44(4): 704-8.
  20. Ong GJ, Page A, Caughey G, Johns S, Reeve E, Shakib S. Clinician agreement and influence of medication-related characteristics on assessment of polypharmacy. Pharmacology research & perspectives 2017; 5(3): e00321.
  21. Ostrow L, Jessell L, Hurd M, Darrow SM, Cohen D. Discontinuing Psychiatric Medications: A Survey of Long-Term Users. Psychiatric services (Washington, DC) 2017; 68(12): 1232-8.
  22. Palagyi A, Keay L, Harper J, Potter J, Lindley RI. Barricades and brickwalls–a qualitative study exploring perceptions of medication use and deprescribing in long-term care. BMC geriatrics 2016; 16: 15.
  23. Reeve E, Bell JS, Hilmer SN. Barriers to Optimising Prescribing and Deprescribing in Older Adults with Dementia: A Narrative Review. Current clinical pharmacology 2015; 10(3): 168-77.
  24. Reeve E, Low LF, Hilmer SN. Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. The British journal of general practice : the journal of the Royal College of General Practitioners 2016; 66(649): e552-60.
  25. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging 2013; 30(10): 793-807.
  26. Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: a real need to deprescribe in older patients. The Medical journal of Australia 2014; 201(7): 390-2.
  27. Scott IA, Gray LC, Martin JH, Pillans PI, Mitchell CA. Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evidence-based medicine 2013; 18(4): 121-4.
  28. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015; 175(5): 827-34.
  29. Slater N, White S, Venables R, Frisher M. Factors associated with polypharmacy in primary care: a cross-sectional analysis of data from The English Longitudinal Study of Ageing (ELSA). BMJ open 2018; 8(3): e020270.
  30. Spinewine A, Swine C, Dhillon S, et al. Appropriateness of use of medicines in elderly inpatients: qualitative study. BMJ (Clinical research ed) 2005; 331(7522): 935.
  31. Uhl MC, Muth C, Gerlach FM, Schoch GG, Muller BS. Patient-perceived barriers and facilitators to the implementation of a medication review in primary care: a qualitative thematic analysis. BMC Fam Pract 2018; 19(1): 3.
  32. Wallis KA, Andrews A, Henderson M. Swimming Against the Tide: Primary Care Physicians’ Views on Deprescribing in Everyday Practice. Annals of family medicine 2017; 15(4): 341-6.

 

Interventions

  1. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS One 2016; 11(4): e0151066.
  2. Anderson C, McNab D. Quality improvement project using a care bundle approach on the management of the immediate discharge document (IDD) within a single general practice. BMJ quality improvement reports 2015; 4(1).
  3. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ open 2014; 4(12): e006544.
  4. Antimisiaris D, Cutler T. Managing Polypharmacy in the 15-Minute Office Visit. Primary care 2017; 44(3): 413-28.
  5. Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc 2008; 56(10): 1946-52.
  6. Bell HT, Granas AG, Enmarker I, Omli R, Steinsbekk A. Nurses’ and pharmacists’ learning experiences from participating in interprofessional medication reviews for elderly in primary health care – a qualitative study. BMC Fam Pract 2017; 18(1): 30.
  7. Best A, Greenhalgh T, Lewis S, Saul JE, Carroll S, Bitz J. Large-system transformation in health care: a realist review. Milbank Q 2012; 90(3): 421-56.
  8. Brandt NJ. Optimizing Medication Use Through Deprescribing: Tactics for This Approach. Journal of gerontological nursing 2016; 42(1): 10-4.
  9. Brownlie K, Schneider C, Culliford R, et al. Medication reconciliation by a pharmacy technician in a mental health assessment unit. International journal of clinical pharmacy 2014; 36(2): 303-9.
  10. Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ open 2015; 5(12): e009235.
  11. Farrell B, Pottie K, Rojas-Fernandez CH, Bjerre LM, Thompson W, Welch V. Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. PLoS One 2016; 11(8): e0161248.
  12. Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Canadian family physician Medecin de famille canadien 2017; 63(5): 354-64.
  13. Farrell B, Richardson L, Raman-Wilms L, de Launay D, Alsabbagh MW, Conklin J. Self-efficacy for deprescribing: A survey for health care professionals using evidence-based deprescribing guidelines. Research in social & administrative pharmacy : RSAP 2018; 14(1): 18-25.
  14. Harrison JK, Van Der Wardt V, Conroy SP, et al. New horizons: the management of hypertension in people with dementia. Age Ageing 2016; 45(6): 740-6.
  15. Howard DH, Gross CP. Producing Evidence to Reduce Low-Value Care. JAMA Intern Med 2015; 175(12): 1893-4.
  16. Jansen J, Naganathan V, Carter SM, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ (Clinical research ed) 2016; 353: i2893.
  17. Johansson T, Abuzahra ME, Keller S, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; 82(2): 532-48.
  18. Kamarudin G, Penm J, Chaar B, Moles R. Educational interventions to improve prescribing competency: a systematic review. BMJ open 2013; 3(8): e003291.
  19. Lader M. Benzodiazepine harm: how can it be reduced? British journal of clinical pharmacology 2014; 77(2): 295-301.
  20. Lee C, Lo A, Ubhi K, Milewski M. Outcome after Discontinuation of Proton Pump Inhibitors at a Residential Care Site: Quality Improvement Project. The Canadian journal of hospital pharmacy 2017; 70(3): 215-23.
  21. Linsky A, Simon SR, Stolzmann K, Meterko M. Patient Perceptions of Deprescribing: Survey Development and Psychometric Assessment. Medical care 2017; 55(3): 306-13.
  22. Maeda K. Systematic review of the effects of improvement of prescription to reduce the number of medications in the elderly with polypharmacy. Yakugaku Zasshi 2009; 129(5): 631-45.
  23. Martin P, Tamblyn R, Ahmed S, Benedetti A, Tannenbaum C. A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trial. Trials 2015; 16: 266.
  24. Marvin V, Ward E, Poots AJ, Heard K, Rajagopalan A, Jubraj B. Deprescribing medicines in the acute setting to reduce the risk of falls. European journal of hospital pharmacy Science and practice 2017; 24(1): 10-5.
  25. Muth C, Beyer M, Fortin M, et al. Multimorbidity’s research challenges and priorities from a clinical perspective: the case of ‘Mr Curran’. The European journal of general practice 2014; 20(2): 139-47.
  26. Ostini R, Hegney D, Jackson C, et al. Systematic review of interventions to improve prescribing. The Annals of pharmacotherapy 2009; 43(3): 502-13.
  27. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; 82(3): 583-623.
  28. Palagyi A, Keay L, Harper J, Potter J, Lindley RI. Barricades and brickwalls–a qualitative study exploring perceptions of medication use and deprescribing in long-term care. BMC geriatrics 2016; 16: 15.
  29. Patton DE, Hughes CM, Cadogan CA, Ryan CA. Theory-Based Interventions to Improve Medication Adherence in Older Adults Prescribed Polypharmacy: A Systematic Review. Drugs Aging 2017; 34(2): 97-113.
  30. Powell AA, Bloomfield HE, Burgess DJ, Wilt TJ, Partin MR. A conceptual framework for understanding and reducing overuse by primary care providers. Med Care Res Rev 2013; 70(5): 451-72.
  31. Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. American family physician 2013; 87(5): 331-6.
  32. Reeve E, Low LF, Hilmer SN. Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. The British journal of general practice : the journal of the Royal College of General Practitioners 2016; 66(649): e552-60.
  33. Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol 2017; 73(8): 927-35.
  34. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging 2003; 20(11): 817-32.
  35. Samala R, Loquias JE, Galindo D, Ciocon J. Reducing nursing home polypharmacy using systematic medication and assessment review and tracking: the SMART Program. J Am Geriatr Soc 2011; 59(9): 1771-3.
  36. Schwartz JB. Primary prevention: do the very elderly require a different approach? Trends in cardiovascular medicine 2015; 25(3): 228-39.
  37. Scott IA, Gray LC, Martin JH, Mitchell CA. Minimizing inappropriate medications in older populations: a 10-step conceptual framework. The American journal of medicine 2012; 125(6): 529-37.e4.
  38. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015; 175(5): 827-34.
  39. Skinner M. A literature review: polypharmacy protocol for primary care. Geriatric nursing (New York, NY) 2015; 36(5): 367-71.e4.
  40. Smith SM, Wallace E, O’Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. The Cochrane database of systematic reviews 2016; 3: Cd006560.
  41. Sonnichsen A, Trampisch US, Rieckert A, et al. Polypharmacy in chronic diseases-Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support (PRIMA-eDS): study protocol for a randomized controlled trial. Trials 2016; 17: 57.
  42. Tani H, Uchida H, Suzuki T, Fujii Y, Mimura M. Interventions to reduce antipsychotic polypharmacy: A systematic review. Schizophr Res 2013; 143(1): 215-20.
  43. Tannenbaum C, Farrell B, Shaw J, et al. An Ecological Approach to Reducing Potentially Inappropriate Medication Use: Canadian Deprescribing Network. Canadian journal on aging = La revue canadienne du vieillissement 2017; 36(1): 97-107.
  44. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med 2014; 174(6): 890-8.
  45. Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of Deprescribing Interventions in Older Hospitalised Patients on Prescribing and Clinical Outcomes: A Systematic Review of Randomised Trials. Drugs Aging 2018.
  46. Trygstad TK, Christensen D, Garmise J, Sullivan R, Wegner S. Pharmacist response to alerts generated from Medicaid pharmacy claims in a long-term care setting: results from the North Carolina polypharmacy initiative. J Manag Care Pharm 2005; 11(7): 575-83.
  47. Tsao CH, Tsai CF, Lee YT, et al. Drug Prescribing in the Elderly Receiving Home Care. The American journal of the medical sciences 2016; 352(2): 134-40.
  48. Van der Linden L, Decoutere L, Walgraeve K, et al. Combined Use of the Rationalization of Home Medication by an Adjusted STOPP in Older Patients (RASP) List and a Pharmacist-Led Medication Review in Very Old Inpatients: Impact on Quality of Prescribing and Clinical Outcome. Drugs Aging 2017; 34(2): 123-33.
  49. Villanyi D, Fok M, Wong RY. Medication reconciliation: identifying medication discrepancies in acutely ill hospitalized older adults. Am J Geriatr Pharmacother 2011; 9(5): 339-44.
  50. Wallis KA, Andrews A, Henderson M. Swimming Against the Tide: Primary Care Physicians’ Views on Deprescribing in Everyday Practice. Annals of family medicine 2017; 15(4): 341-6.
  51. Weiner S, Fink JC. Telemedicine to Promote Patient Safety: Use of Phone-Based Interactive Voice-Response System to Reduce Adverse Safety Events in Pre-dialysis CKD. Advances in chronic kidney disease 2017; 24(1): 31-8.
  52. Wilsdon TD, Hendrix I, Thynne TR, Mangoni AA. Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults. Drugs Aging 2017; 34(4): 265-87.
  53. Young A, Tordoff J, Dovey S, et al. Using an Electronic Decision Support Tool to Reduce Inappropriate Polypharmacy and Optimize Medicines: Rationale and Methods. JMIR research protocols 2016; 5(2): e105.
  54. Young SL, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. Journal of psychopharmacology (Oxford, England) 2015; 29(4): 353-62.
  55. Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy 2005; 25(11): 1636-45.
  56. Zullo AR, Gray SL, Holmes HM, Marcum ZA. Screening for Medication Appropriateness in Older Adults. Clinics in geriatric medicine 2018; 34(1): 39-54.

 

Specific Drugs of Interest

  1. Al Khaja KA, Sequeira RP, Damanhori AH. Medication prescribing errors pertaining to cardiovascular/antidiabetic medications: a prescription audit in primary care. Fundamental & clinical pharmacology 2012; 26(3): 410-7.
  2. Alessi-Severini S, Dahl M, Schultz J, Metge C, Raymond C. Prescribing of psychotropic medications to the elderly population of a Canadian province: a retrospective study using administrative databases. PeerJ 2013; 1: e168.
  3. Barras MA, Hughes D, Ullner M. Direct oral anticoagulants: New drugs with practical problems. How can nurses help prevent patient harm? Nursing & health sciences 2016; 18(3): 408-11.
  4. Brett J, Maust DT, Bouck Z, et al. Benzodiazepine Use in Older Adults in the United States, Ontario, and Australia from 2010 to 2016. J Am Geriatr Soc 2018.
  5. Chutka DS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo Clinic proceedings 2004; 79(1): 122-39.
  6. Connolly A, Taylor D. Factors associated with non evidence-based prescribing of antipsychotics. Ther Adv Psychopharmacol 2014; 4(6): 247-56.
  7. Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 2013; 30(8): 613-28.
  8. Fornaro M, De Berardis D, Koshy AS, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat 2016; 12: 719-35.
  9. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138(1): 18-28.
  10. Hanlon JT, Aspinall SL, Handler SM, et al. Potentially suboptimal prescribing for older veteran nursing home patients with dementia. The Annals of pharmacotherapy 2015; 49(1): 20-8.
  11. Pitkala KH, Juola AL, Soini H, et al. Reducing inappropriate, anticholinergic and psychotropic drugs among older residents in assisted living facilities: study protocol for a randomized controlled trial. Trials 2012; 13: 85.
  12. Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Can J Psychiatry 2015; 60(5): 215-22.
  13. Young SL, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. Journal of psychopharmacology (Oxford, England) 2015; 29(4): 353-62.